197,951 Shares in Thermo Fisher Scientific Inc. $TMO Purchased by Strs Ohio

Strs Ohio purchased a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 197,951 shares of the medical research company’s stock, valued at approximately $98,500,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. GAMMA Investing LLC lifted its position in Thermo Fisher Scientific by 60,610.9% during the first quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company’s stock worth $1,203,859,000 after acquiring an additional 2,415,346 shares during the last quarter. Nuveen LLC acquired a new stake in Thermo Fisher Scientific during the first quarter worth approximately $532,360,000. Sarasin & Partners LLP acquired a new stake in Thermo Fisher Scientific during the first quarter worth approximately $242,991,000. Two Sigma Advisers LP lifted its position in Thermo Fisher Scientific by 81.6% during the fourth quarter. Two Sigma Advisers LP now owns 933,200 shares of the medical research company’s stock worth $485,479,000 after acquiring an additional 419,200 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Thermo Fisher Scientific during the fourth quarter worth approximately $195,049,000. Institutional investors own 89.23% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Marc N. Casper sold 400 shares of the business’s stock in a transaction on Friday, September 5th. The shares were sold at an average price of $500.50, for a total value of $200,200.00. Following the sale, the chief executive officer owned 113,762 shares of the company’s stock, valued at $56,937,881. The trade was a 0.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares in the company, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 30,066 shares of company stock valued at $14,182,963. 0.33% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. Wall Street Zen downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Sunday. Barclays lifted their price target on shares of Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an “equal weight” rating in a research report on Thursday, July 24th. Robert W. Baird lifted their price target on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an “outperform” rating in a research report on Thursday, July 24th. HSBC reiterated a “hold” rating and issued a $510.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Finally, Royal Bank Of Canada set a $561.00 price target on shares of Thermo Fisher Scientific and gave the company an “outperform” rating in a research report on Tuesday, September 2nd. Sixteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $589.38.

Thermo Fisher Scientific Stock Down 1.1%

Shares of TMO opened at $477.03 on Thursday. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $623.77. The company has a market cap of $180.13 billion, a P/E ratio of 27.59, a P/E/G ratio of 2.58 and a beta of 0.75. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The firm has a 50 day simple moving average of $464.58 and a two-hundred day simple moving average of $452.37.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same period in the previous year, the business earned $5.37 earnings per share. The company’s revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific’s payout ratio is presently 9.95%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.